Alira Health

Alira Health

Alira Health Strengthens Growth Strategy with $35M Funding, led by Creadev

The firm’s partnership with industrial family investors, led by the Mulliez family investment arm, will accelerate growth and fuel the development of technology and solutions-enabled services.

News
Published on:
April 12, 2021

FRAMINGHAM, Mass. – April 12, 2021 – Alira Health (www.alirahealth.com), a leading international advisory firm dedicated to advancing healthcare and life sciences , announced it has closed a $35M equity financing led by Creadev, an evergreen investment company backed by the Mulliez family. This new partnership will help accelerate the firm’s growth strategy, focused on merging pharmaceutical, medical and digital technologies development with medical care through a patient-centric approach.

Gabriele Brambilla

“I would like to thank our team of investors for joining our mission to enable healthcare transformation. Their investment positions us to change the way life sciences advisory services are delivered,” said Gabriele Brambilla, Chief Executive Officer and Co-Founder of Alira Health. “We are building a powerful continuum of services that spans the product and solutions development life cycle, supported by the recent additions of our patient engagement, real-world evidence and advanced analytics practices. This financing allows us to advance the science and strategy of healthcare with our clients, ultimately enhancing patient outcomes.”

Benjamin Chambon

“We were looking for investors who would recognize the value of our mission, bring new perspectives to our approach, and partner with us for a long-term, ambitious plan of innovative and global growth. We are honored that Creadev, together with two other life sciences industrial families, chose to join Alira Health and support our leadership and vision“ said Benjamin Chambon, Chief Commercial Officer and Co-Founder of Alira Health.

 

“The Creadev team is proud to partner with Alira Health,” said Yohann Gbahoué, Executive Director, Creadev. “Alira Health’s approach to healthcare advisory is pioneering, and we see the impact of their work on patient outcomes growing as the company continues to implement their strategic vision. We join the entire investment team in congratulating Gabriele and the firm and look forward to supporting their future growth.”

The group of new investors will hold a minority interest in Alira Health. This operation empowers the company to accelerate the development of their technology-enabled services and boost the firm’s inorganic growth strategy in the U.S. and EU.

Advisors to Creadev: Finance & Tax (Alvarez & Marsal), Legal (King & Spalding), IT/Data (Z Consulting), HR (Selescope)

Advisors to Alira Health: Equiteq represented Alira Health in the transaction

About Creadev:
Creadev is an evergreen investment firm operating worldwide, controlled by the Mulliez family, founders of one of the largest Business to Consumer retail platforms in the world. Creadev is committed to long-term collaboration with innovative, passionate, and human-driven entrepreneurs that are focused on creating widespread access to essential goods and services such as healthcare, sustainable consumption and food. Based in Paris, and with offices in New-York, Shanghai and Nairobi, Creadev invests in companies well positioned to scale and become worldwide leaders in their respective sectors. Launched in 2002, Creadev has invested over €1.8 Bn in companies in stages ranging from venture to growth equity and buyout.

Read the press release on BusinessWire here.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Mauris urna arcu, tempor ut laoreet eu, consectetur in mi. Maecenas rhoncus velit eget metus dignissim, sed bibendum elit lacinia. Mauris tristique, nisi ac sollicitudin dignissim, dui ipsum suscipit nulla, vitae sodales neque mauris vel est. Duis est velit, efficitur eget rutrum non, interdum et erat. Duis elit arcu, tristique quis feugiat quis, tincidunt tempus ligula. In hac habitasse platea dictumst. Ut dolor neque, egestas quis accumsan at, egestas sit amet leo.

Related news

Reports May 20, 2024
Innovative Payment Schemes for Medtech in England, Germany, and France
This overview offers high-level details on the innovative payment schemes in England, Germany, and France.
MedTech
Case Studies May 14, 2024
Medtech Company Creates an Early Go-to-Market Strategy for Its Breakthrough IVD Solution
The client needed an early go-to-market strategy for their IVD solution to prepare for product development and launch in key European countries and the US.
IVDR Medical Devices MedTech
Case Studies May 8, 2024
Mid-Size Medtech Company with a Borderline Product Defines Strategy for EU Launch
Medtech company sought support in developing a regulatory strategy for the EU launch of their product with an aggressive timeline to launch.
Medical Devices MedTech Regulatory
Reports May 8, 2024
Value-Based Procurement in Australia
This white paper discusses why value-based healthcare and procurement are solutions in a robust healthcare system and identifies the medical technology sector as a collaborative partner(...)
MedTech Value-Based Contracts
Case Studies April 30, 2024
Medtech Company Leverages Bayesian Clinical Trial Design to Address FDA Feedback
A global medtech company needed help to address FDA feedback on their implant design that included a comparator and clearly demonstrated the safety and performance of this new device.
Clinical Trials Complex Innovative Design MedTech
Events April 30, 2024
The MedTech Forum 2024
We are thrilled to announce that we will exhibit and speak at The MedTech Forum 2024.
MedTech Regulatory
News April 29, 2024
Alira Health Advises Trill Impact Entering a Strategic Alliance with TT medic
We are pleased to have been a Commercial Due Diligence advisor for Trill Impact, a pioneering Impact House with around EUR 1.2 billion in assets under management, joining forces with(...)
CDD CDMO MedTech
Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.